“Gilead announced the China Food and Drug Administration (CFDA) approved Sovaldi (sofosbuvir 400 mg) for the treatment of adults and adolescent patients with chronic hepatitis C virus infection (pan-genotypes).”
According to TipRanks.com, Zhou is a 5-star analyst with an average return of 26.1% and a 58.9% success rate. Zhou covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, ContraVir Pharmaceuticals Inc, and Cellular Biomedicine Group.
Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $87.85.
The company has a one year high of $86.27 and a one year low of $63.76. Currently, Gilead Sciences has an average volume of 9.35M.
Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Robin Washington, the EVP, CFO of GILD sold 33,750 shares for a total of $2,868,750.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.